Utilization of telemetry system to assess the cardiovascular profile of AH-1058, a new cardioselective Ca2+ channel blocker, in conscious dogs.
Cardiovascular effects of a new Ca2+ channel blocker AH-1058, 4-(5H-dibenzo[a,d]cyclo-hepten-5-ylidene)-1-[(E)-3-(3-methoxy-2-nitro)phenyl-2-propenyl]piperidine hydrochloride, were assessed in conscious dogs using a new telemetry system. AH-1058 (0.03, 0.1 and 0.3 mg/kg, i.v.) reduced systolic blood pressure and the maximal upstroke velocity of the left ventricular pressure and increased the heart rate in a dose-dependent manner without affecting the diastolic blood pressure; each of these responses lasted for several hours. These results support the previous knowledge that AH-1058 is a long-lasting cardiodepressive drug. The telemetry system provided important information for predicting favorable clinical effects of AH-1058.
Takahara
A
A
Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., Kawasaki, Japan. akira_takahara@ajinomoto.com
Dohmoto
H
H
Yoshimoto
R
R
Sugiyama
A
A
Hashimoto
K
K
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D004285:Dogs; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology*; D013686:Telemetry; D016277:Ventricular Function, Left / Q000187:drug effects; D017725:Ventricular Pressure / Q000187:drug effects
D001643:Bridged Bicyclo Compounds; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D010880:Piperidines; C119283:AH 1058